SELLAS Shares Rise 20% as It Expects Leukemia Trial Results This Month

SELLAS Life Sciences Group, Inc. (SLS) shares rose 20% in extended trading Thursday after the company set expectations for results from its pivotal leukemia trial this month. SELLAS also posted a quarterly loss per share in line with Wall Street expectations.

Phase 3 REGAL is testing galinpepimut-S (GPS) in acute myeloid leukemia. On Oct. 28, SELLAS said the trial reached its prespecified 80th death event, triggering final analysis, as detailed in our earlier coverage of the trial milestone. At the time, topline results for the primary endpoint were expected in the fourth quarter.

SELLAS now expects the data this month, narrowing the timing to November within that quarter. The upcoming readout concerns REGAL’s primary endpoint.